RT Journal Article
SR Electronic
T1 Feasibility of non-invasive nitric oxide inhalation in acute hypoxemic respiratory failure: potential role during the COVID-19 pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.17.20082123
DO 10.1101/2020.05.17.20082123
A1 Kiran Shekar
A1 Sneha Varkey
A1 George Cornmell
A1 Leanne Parsons
A1 Maneesha Tol
A1 Matthew Siuba
A1 Mahesh Ramanan
YR 2020
UL http://medrxiv.org/content/early/2020/05/20/2020.05.17.20082123.abstract
AB Acute hypoxemic respiratory failure (ARF) is characterized by both lower arterial oxygen and carbon dioxide tensions in the blood. First line treatment for ARF includes oxygen therapy – intially admininstered non invasively using nasal prongs, high flow nasal cannulae or masks. Invasive mechancial ventilation (IMV) is usually reserved for patients who are unable to maintain their airway, those with worsening hypoxemia, or those who develop respiratory muscle fatigue and consequent hypercapnia.Inhaled nitric oxide (iNO) gas is known to improve oxygenation in patients with ARF by manipulating ventilation-perfusion matching. Addition of iNO may potentially alleviate the need for IMV in selected patients. This article demonstrates the feasibility of this technique based on our experience of patients with hypoxemic ARF. This technique may also be considered for patients with hypoxic ARF in setting of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNone relevantAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo external datasets provided